Overview
Title
To amend the Public Health Service Act to expand research and education with respect to endometrial cancer, and for other purposes.
ELI5 AI
The bill wants to help doctors learn more about a type of cancer that mainly affects women and teach people about it, especially making sure to include African-American women in the studies. It also tries to tell everyone about the cancer and how to stay healthy, but it needs more clear rules about how much money will be used for these activities.
Summary AI
H.R. 10439, titled the “Endometrial Cancer Research and Education Act of 2024,” aims to update the Public Health Service Act to enhance research and educational efforts related to endometrial cancer. The bill proposes the expansion and coordination of research programs, particularly highlighting disparities in diagnosis rates between African-American and non-Hispanic White women. It also mandates the inclusion of African-American women in clinical trials. Additionally, the Centers for Disease Control and Prevention (CDC) is tasked with creating and distributing materials to inform the public about endometrial cancer, focusing on high-risk groups and available treatments.
Published
Keywords AI
Sources
Bill Statistics
Size
Language
Complexity
AnalysisAI
The proposed legislation, known as the "Endometrial Cancer Research and Education Act of 2024," aims to amend the Public Health Service Act to enhance research and educational efforts concerning endometrial cancer. This bill, introduced in the 118th Congress, acknowledges the rising incidence of endometrial cancer, particularly among African-American and Asian women, and seeks to address disparities in diagnosis and mortality rates.
General Summary of the Bill
The bill focuses on expanding research and educational initiatives on endometrial cancer, directing both the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) to spearhead these efforts. It proposes specific actions to increase awareness and understanding of the disease, especially in minority communities, and to ensure greater representation of African-American women in clinical trials. To facilitate these objectives, the bill authorizes budget allocations for the fiscal years from 2025 through 2027.
Significant Issues Identified
One of the main concerns is the funding specifics. The bill allocates a fixed annual budget of $500,000 for the NIH's research initiatives, which may fall short of covering the extensive scope required to tackle the complexities of endometrial cancer. Additionally, the CDC's public education program is funded with an open-ended budget, described as "such sums as may be necessary," potentially leading to excessive spending without strict accountability.
Another significant issue lies in the clinical trial requirements. The mandate for all NIH-supported trials to include at least one African-American woman aims to address demographic disparities but may present practical challenges, particularly for smaller trials that may face logistical difficulties meeting this requirement.
Impact on the Public and Stakeholders
Broadly speaking, the bill has the potential to significantly raise awareness about endometrial cancer and its increased risks among minority women. By promoting research and educational outreach, it might lead to earlier diagnoses and improved outcomes for women affected by this disease, particularly those from underserved communities.
For healthcare providers and researchers, this initiative provides an opportunity to focus on a previously underrepresented area of study. However, practical hurdles, such as the coordination across multiple institutes and the complexities of inclusive clinical trials, may require additional resources and strategic planning to overcome.
Positive and Negative Impacts on Stakeholders
Positive Impacts:
- Patients: Women who are at risk or currently battling endometrial cancer could benefit from increased awareness and potentially improved healthcare outcomes due to more focused research and education.
- African-American and Minority Communities: Specific attention to these groups may help address health disparities, providing a platform for more equitable healthcare solutions.
Negative Impacts:
- Healthcare and Research Institutions: They may face challenges in implementing the bill's mandates, especially concerning trial inclusivity and coordination with various organizations, which can stretch resources.
- Other Minority Groups: While the spotlight is on African-American women, other underserved groups might feel overlooked if similar initiatives are not directed at their populations.
In conclusion, the "Endometrial Cancer Research and Education Act of 2024" targets a vital issue within women's health, with an emphasis on addressing racial and ethnic disparities. While it holds promise for improving patient outcomes and fostering inclusive healthcare research, the success of its implementation will largely depend on the adequacy of allocated resources and the ability to navigate the logistical and practical challenges presented by its mandates.
Financial Assessment
The bill titled "Endometrial Cancer Research and Education Act of 2024" aims to allocate funds specifically for research and education surrounding endometrial cancer. The financial provisions outlined in the bill are essential to understand as they direct how resources will be designated toward achieving the bill's aims.
Funding Allocations
The bill authorizes a fixed sum of $500,000 per year for the fiscal years 2025 through 2027 to support the efforts of the National Institutes of Health (NIH) in expanding, intensifying, and coordinating research on endometrial cancer. This allocation aims at addressing disparities particularly affecting African-American women in terms of diagnosis and survival rates. However, the fixed nature of this allocation may be seen as potentially limiting. Given the complexity of endometrial cancer research and the goal of addressing racial disparities, $500,000 annually may not be sufficient to cover the comprehensive research needs, which include clinical trials, disparity investigations, and public education efforts.
Additionally, the Centers for Disease Control and Prevention (CDC) is tasked with developing an Endometrial Cancer Public Education Program. Unlike the NIH funding, the financial allocation for this program is described in more ambiguous terms as “such sums as may be necessary” for the same fiscal years. This open-ended financial phrasing can lead to concerns over unchecked spending, as it lacks defined budget constraints and potentially decreases accountability. Clarity in funding limits or guidelines would help ensure fiscal responsibility and effective use of allocated resources.
Implementation Challenges
One notable requirement of the bill is that all NIH-supported clinical trials include at least one African-American woman. From a funding perspective, this mandate may present practical challenges, particularly for smaller-scale studies that may face feasibility issues in reaching participant quotas. This requirement could potentially inflate study costs or, conversely, limit the scope of research if additional financial resources are not provided.
Moreover, the bill calls for coordination between several NIH-related institutes, raising potential administrative and budgetary complexities. Coordination across various institutes can be resource-intensive, and if not managed efficiently, may lead to delays or duplication of efforts. The administrative costs associated with such coordination are not specifically addressed within the financial allocations, posing an implicit risk to the effectiveness of fund utilization.
Effectiveness and Equity Concerns
Lastly, there is no clear provision for metrics to measure the impact or efficiency of the CDC's public education program. This absence of specific outcome metrics poses the risk of ineffective spending without clear paths to evaluate success or areas needing improvement. Additionally, while the program targets African-American women, the bill's focus might inadvertently divert attention and resources from other underserved groups who may also benefit from such programs, potentially leading to criticisms of inequity in fund distribution.
In summary, while the bill establishes a foundation for addressing crucial issues in endometrial cancer research and education, the financial allocations and language present challenges and limitations that require careful consideration and planning to effectively harness resources for maximum impact.
Issues
The bill assigns a fixed sum of $500,000 per year for fiscal years 2025 through 2027 for NIH's research and education on endometrial cancer, which may be insufficient given the complexity and breadth required to comprehensively address the disease and its specific impacts on African-American women (Sections 3 and 409K).
The broad language 'such sums as may be necessary' for the CDC's Endometrial Cancer Public Education Program lacks specificity in budget constraints, potentially leading to unrestricted spending without clear accountability (Section 399V-8).
The requirement in the bill that all NIH-supported clinical trials include at least one African-American woman may pose practical challenges, particularly for small-scale studies, raising concerns about the implementation and feasibility of such mandates (Section 409K).
The coordination mandate between multiple institutes and offices, such as NIH, the National Institute on Minority Health and Health Disparities, and others, while necessary, might lead to administrative complexity and delays if not managed efficiently (Section 409K).
There is a lack of outlined metrics for measuring the effectiveness of the public education program, which poses a risk of inefficiencies or spending without clear outcomes (Section 399V-8).
The findings section outlines demographic disparities in endometrial cancer incidence and mortality rates but does not propose specific solutions or measures to address systemic factors contributing to these disparities (Section 2).
The text mandates specific informational targeting toward African-American women, potentially omitting similar attention for other underserved groups, which could lead to criticism regarding the equitable distribution of resources and attention (Sections 3 and 399V-8).
Sections
Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.
1. Short title Read Opens in new tab
Summary AI
The first section of the act gives it a short title, allowing it to be referred to as the "Endometrial Cancer Research and Education Act of 2024."
2. Findings Read Opens in new tab
Summary AI
Congress has found that endometrial cancer, which is the most common type of uterine cancer and mainly affects postmenopausal women, is increasing in the U.S., particularly among African-American and Asian women. Although non-Hispanic White women are more often diagnosed with this cancer than African-American women, African-American women face higher mortality rates, and the reasons for this disparity remain unclear, with researchers pointing to factors like delays in care and socioeconomic conditions.
3. Expanding research and education with respect to endometrial cancer Read Opens in new tab
Summary AI
The bill proposes expanding research and education on endometrial cancer, highlighting the need for more inclusive clinical trials involving African-American women, and coordinating efforts across health institutes. It also requires the CDC to create and share educational materials about endometrial cancer, focusing on its impact on ethnic minority women, with funding authorized for these initiatives for the fiscal years 2025 to 2027.
Money References
- “(c) Authorization of appropriations.—For purposes of carrying out this section, there is authorized to be appropriated $500,000 for each of fiscal years 2025 through 2027.”. (b) Centers for Disease Control and Prevention.—Part P of title III of the Public Health Service Act (42 U.S.C. 280g et seq.)
409K. Endometrial cancer Read Opens in new tab
Summary AI
The section directs the Director of the National Institutes of Health (NIH) to enhance research on endometrial cancer, communicate disparities in diagnoses between African-American and non-Hispanic White women, and ensure African-American women's participation in related clinical trials. It also mandates cooperation with other health institutes and authorizes $500,000 annually from 2025 to 2027 for these activities.
Money References
- (a) In general.—The Director of NIH shall— (1) expand, intensify, and coordinate programs to conduct and support research with respect to endometrial cancer; (2) communicate to medical professionals and researchers, including through the endometrial cancer public education program established under section 399V–8, the disparity in the diagnosis of endometrial cancer between African-American women and non-Hispanic White women and any new research relating to endometrial cancer; and (3) ensure that all clinical trials conducted or supported by the National Institutes of Health with respect to endometrial cancer include at least 1 participant who is an African-American woman. (b) Coordination with other institutes.—The Director of NIH shall coordinate activities carried out by the Director pursuant to subsection (a) with similar activities carried out by— (1) the Director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development; (2) the Director of the National Institute on Minority Health and Health Disparities; and (3) the Director of the Office of Research on Women’s Health. (c) Authorization of appropriations.—For purposes of carrying out this section, there is authorized to be appropriated $500,000 for each of fiscal years 2025 through 2027.
399V–8. Endometrial Cancer Public Education Program Read Opens in new tab
Summary AI
The Secretary, through the CDC Director, is tasked with creating and sharing informational materials about endometrial cancer, focusing on its incidence, risk factors, impact on minority women, and treatments. These materials must include content specifically for African-American women, and the CDC must collaborate with the Health Resources and Services Administration, with necessary funding authorized for 2025 to 2027.